MREO

MREO

USD

Mereo BioPharma Group plc American Depositary Shares

$1.780-0.050 (-2.732%)

السعر في الوقت الحقيقي

Healthcare
التكنولوجيا الحيوية
المملكة المتحدة

مخطط الأسعار

Loading Chart...

المقاييس الرئيسية

مقاييس السوق
أساسيات الشركة
إحصاءات التداول

مقاييس السوق

الافتتاح

$1.830

الأعلى

$1.880

الأدنى

$1.780

الحجم

1.12M

أساسيات الشركة

القيمة السوقية

283.2M

الصناعة

التكنولوجيا الحيوية

البلد

United Kingdom

إحصاءات التداول

متوسط الحجم

1.32M

البورصة

NCM

العملة

USD

نطاق 52 أسبوعاً

الأدنى $1.47الحالي $1.780الأعلى $4.395

أخبار ذات صلة

PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO

Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc ("Mereo" or the "Company") (NASDAQ: MREO). Such investors...

عرض المزيد
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
Analyst Upgrades

JP Morgan Maintains Overweight on Mereo BioPharma Group, Raises Price Target to $8

JP Morgan analyst Priyanka Grover maintains Mereo BioPharma Group with a Overweight and raises the price target from $7 to $8.

عرض المزيد
JP Morgan Maintains Overweight on Mereo BioPharma Group, Raises Price Target to $8
PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO

Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc ("Mereo" or the "Company") (NASDAQ: MREO). Such investors...

عرض المزيد
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
BusinessWire

āshibio Expands Clinical Pipeline with Vantictumab, a First-In-Class Antibody for Autosomal Dominant Osteopetrosis Type 2

- Company's second clinical-stage asset licensed from Mereo Biopharma based on novel insights generated in a mouse model of osteopetrosis - - āshibio has exclusive license to develop and commercialize vantictumab

عرض المزيد
āshibio Expands Clinical Pipeline with Vantictumab, a First-In-Class Antibody for Autosomal Dominant Osteopetrosis Type 2
GlobeNewswire

Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights

Data from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta expected around year-end 2025 Cash of $56.1 million as of June 30, 2025, expected to support operations into 2027 LONDON, Aug. 12,

عرض المزيد
Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights
PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO

Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc ("Mereo" or the "Company") (NASDAQ: MREO). Such investors...

ابق على اطلاع

تعيين تنبيهات الأسعار، الحصول على تحديثات تحليل الذكاء الاصطناعي وأخبار السوق في الوقت الحقيقي.